Telomir Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, December 31, 2025 | 34,380,971 | $— | $46,923,433 | $(41,010,063) | $5,913,370 |
| Stock-based compensation | — | — | 39,803 | — | 39,803 |
| Net loss | — | — | — | (990,947) | (990,947) |
| Balances, March 31, 2026 | 34,380,971 | $— | $46,963,236 | $(42,001,010) | $4,962,226 |
| Stock-based compensation | — | — | 198,734 | — | 198,734 |
| Issuance of common stock for cash in ATM, net | 4,275 | — | 6,311 | — | 6,311 |
| Stock-based compensation – stock option modification | — | — | 587,737 | — | 587,737 |
| Issuance of common stock – TELI acquisition | 34,389,710 | — | 1,000,000 | — | 1,000,000 |
| Net loss | — | — | — | (1,721,528) | (1,721,528) |
| Balances, June 30, 2026 | 68,774,956 | $— | $48,756,018 | $(43,722,538) | $5,033,480 |
| Stock-based compensation | — | — | 65,344 | — | 65,344 |
| Stock-based compensation – stock option modification | — | — | 11,000 | — | 11,000 |
| Net loss | — | — | — | (705,225) | (705,225) |
| Balances, September 30, 2026 | 68,774,956 | $— | $48,832,362 | $(44,427,763) | $4,404,599 |
| Balances, December 31, 2024 | 29,762,671 | $— | $31,239,895 | $(30,596,858) | $643,037 |
| Stock-based compensation | — | — | 1,375,686 | — | 1,375,686 |
| Net loss | — | — | — | (2,179,828) | (2,179,828) |
| Balances, March 31, 2025 | 29,762,671 | $— | $32,615,581 | $(32,776,686) | $(161,105) |
| Issuance of common stock for cash in ATM, net | 18,299 | — | 47,769 | — | 47,769 |
| Issuance of common stock for cash, Related party | 333,334 | — | 1,000,000 | — | 1,000,000 |
| Issuance of common stock for services | 400,000 | — | 840,000 | — | 840,000 |
| Stock-based compensation | — | — | 3,824,450 | — | 3,824,450 |
| Net loss | — | — | — | (5,069,890) | (5,069,890) |
| Balances, June 30, 2025 | 30,514,304 | $— | $38,327,799 | $(37,846,576) | $481,223 |
| Issuance of common stock for cash in ATM, net | 2,650,000 | — | 5,502,239 | — | 5,502,239 |
| Issuance of common stock for cash, Related party | 666,667 | — | 2,000,000 | — | 2,000,000 |
| Stock-based compensation | — | — | 98,142 | — | 98,142 |
| Net loss | — | — | — | (1,102,294) | (1,102,294) |
| Balances, September 30, 2025 | 33,380,971 | $— | $45,928,180 | $(38,948,870) | $6,979,310 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.